Dosage and administration
Before, during and after pregnancy, take one Vitafol ® Strip daily, or as directed by a physician.
Vitafol
- Manufacturer
- Exeltis USA, Inc. | Aquestive Therapeutics, Inc.
- Effective date
- 2021-01-14
- Label type
- HUMAN PRESCRIPTION DRUG LABEL
- Version
- 2
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 22:56:28
Label at a glance#
ProductVitafol
Active ingredientCHOLECALCIFEROL, Pyridoxine Hydrochloride, Cyanocobalamin, Folic Acid
Label structure10 sections
Contacts and useful links#
Websitewww.fda.gov
www.fda.gov/medwatch
www.fda.gov/medwatchWebsitewww.exeltisusa.com
www.exeltisUSA.com
www.exeltisUSA.comLabel contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
0642-7468-30
Rx Only
| These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. |
COMPOSITION
Amount per daily dose (1 strip)
| VITAMINS AND MINERALS: | |
|---|---|
| Calories | 1 |
| Total Carbohydrates | 0 g |
| Sugars | 0 g |
| Vitamin B6 (as pyridoxine hydrochloride) | 2.5 mg |
| Folic Acid | 1 mg |
| Vitamin B12 (as cyanocobalamin) | 12 mcg |
| Vitamin D (as cholecalciferol) | 1000 IU |
Other Ingredients:
Sentry Polyox WSR N80 LEO, maltitol syrup, methocel (hydroxypropyl methylcellulose), sodium citrate anhydrous, lemon flavor, sucralose, butylated hydroxytoluene, peceol, water.
USAGE
Vitafol® Strips provides vitamin and mineral supplementation prior to conception, throughout pregnancy, and postnatal period for the lactating and non-lactating women.
CONTRAINDICATIONS
Vitafol® Strips is contraindicated in patients with hypersensitivity to any of its components or color additives.
Folic acid is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid.
Cyanocobalamin is contraindicated in patients with sensitivity to cobalt or to cyanocobalamin (vitamin B12).
WARNINGS/PRECAUTIONS
This product is intended for use as directed by your healthcare provider. Please do not share with others.
Vitamin D supplementation should be used with caution in those with hypercalcemia or conditions that may lead to hypercalcemia such as hyperparathyroidism and those who form calcium-containing kidney stones. High doses of vitamin D can lead to elevated levels of calcium that reside in the blood and soft tissues. Bone pain, high blood pressure, formation of kidney stones, renal failure, and increased risk of heart disease can occur.
Folic acid, especially in doses above 0.1 mg daily, may obscure pernicious anemia, in that hematologic remission may occur while neurological manifestations remain progressive.
The use of folic acid doses above 1 mg daily may precipitate or exacerbate the neurological damage of vitamin B12 deficiency.
Do not use if inner seal is broken or missing.
Do not exceed recommended dose.
Keep out of the reach of children.
DRUG INTERACTIONS
Medications for an overactive thyroid (anti-thyroid drugs) used in conjunction with iodine supplementation may lead to hypothyroidism.
Medications for hypertension used in conjunction with iodine supplementation may increase potassium.
High doses of folic acid may result in decreased serum levels of the anticonvulsant drugs; carbamazepine, fosphenytoin, phenytoin, phenobarbitol, valproic acid. Folic acid may decrease a patient's response to methotrexate.
Vitamin D supplementation should not be given with large amounts of calcium in those with hypercalcemia or conditions that may lead to hypercalcemia such as hyperparathyroidism and those who form calcium-containing kidney stones.
Consult appropriate references for additional specific vitamin-drug interactions.
Information for Patients
Patients should be counseled to disclose all medical conditions, including use of all medications, vitamins and supplements, pregnancy, and breast-feeding.
Pediatric Use
Not for pediatric use.
ADVERSE REACTIONS
Adverse reactions have been reported with specific vitamins and minerals, but generally at doses substantially higher than those in Vitafol® Strips. However, allergic and idiosyncratic reactions are possible at any dose. Reported adverse events include skin ailments, gastrointestinal complaints, glucose abnormalities, and visual problems.
DIRECTIONS FOR USE
Before, during and after pregnancy, take one Vitafol® Strip daily, or as directed by a physician.
HOW SUPPLIED
Vitafol® Strips is available as an orange rectangular film with "V" logo printed on one side. Available in Box of Unit-Dose pack in pouch of 30 counts, Item No. 0642-7468-30 and as physician sample in pouch of 3 counts, Item No. 0642-7468-01.
STORAGE AND HANDLING SECTION
Store at room temperature, approximately 20°-25°C (68°-77°F), avoid excessive heat, moisture and protect from light.
To report suspected adverse event contact Exeltis USA, Inc., at 1-877-324-9349 or at FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
SPL UNCLASSIFIED SECTION
Made in USA.
Distributed by:
Exeltis USA, Inc.
Florham Park, NJ 07932
1-877-324-9349www.exeltisUSA.com
©2018 Exeltis USA, Inc.
Vitafol® is a trademark of Exeltis USA, Inc.
Rev. August 2018
4683001-01
PRINCIPAL DISPLAY PANEL - 30 Strip Pouch Box
0642-7468-30
VITAFOL
STRIPS
Prenatal Supplement Strips
with 1 mg folic acid
Fast Dissolving Strip
Unit Dose Pack / 30 Strips
Rx Only
DIETARY SUPPLEMENT
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 0642-7468-01 | 2024-10-14 | C162847 | 48780-1 | e4f33bdf-9eae-d8a0-e053-dadaa90a6e4e | Vitafol ® Strips Prenatal Supplement |
| 0642-7468-30 | 2024-10-14 | C162847 | 48780-1 | e4f33bdf-9eae-d8a0-e053-dadaa90a6e4e | Vitafol ® Strips Prenatal Supplement |
| 0642-7468-01 | 2022-07-29 | C162847 | 48780-1 | e4f33bdf-9eae-d8a0-e053-dadaa90a6e4e | Vitafol ® Strips Prenatal Supplement |
| 0642-7468-30 | 2022-07-29 | C162847 | 48780-1 | e4f33bdf-9eae-d8a0-e053-dadaa90a6e4e | Vitafol ® Strips Prenatal Supplement |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0642-7468-30 | EA - Each | 0642-7468 | 10afa5c1-ffb3-42a7-b55e-a6191d5da7a0 | 1 | 2019-07-02 |
Products#
Every source-derived product name is available through these pages.
- Vitafol
- CHOLECALCIFEROL, Pyridoxine Hydrochloride, Cyanocobalamin, and Folic Acid
- CHOLECALCIFEROL
- Pyridoxine Hydrochloride
- PYRIDOXINE
- Cyanocobalamin
- Folic Acid
- WATER
- MALTITOL
- HYPROMELLOSE 2906 (4000 MPA.S)
- ANHYDROUS TRISODIUM CITRATE
- Sucralose
- BUTYLATED HYDROXYTOLUENE
- GLYCERYL OLEATE
- 1-METHYLCYCLOHEXA-1,3-DIENE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 0642-7468 | 0642-7468-30, 0642-7468-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CHOLECALCIFEROL | 1C6V77QF41 | ACTIB |
| Pyridoxine Hydrochloride | 68Y4CF58BV | ACTIB |
| Cyanocobalamin | P6YC3EG204 | ACTIB |
| Folic Acid | 935E97BOY8 | ACTIB |
| WATER | 059QF0KO0R | IACT |
| MALTITOL | D65DG142WK | IACT |
| HYPROMELLOSE 2906 (4000 MPA.S) | 5EYA69XGAT | IACT |
| ANHYDROUS TRISODIUM CITRATE | RS7A450LGA | IACT |
| Sucralose | 96K6UQ3ZD4 | IACT |
| BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | IACT |
| GLYCERYL OLEATE | 4PC054V79P | IACT |
| 1-METHYLCYCLOHEXA-1,3-DIENE | NZ9H475GT1 | IACT |
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 246d93ed-8f04-9994-e063-6394a90a9d58 | 83f55f74-1641-4a6a-bbc0-002f1ade879b | 2024-10-14 | Warnings, Adverse reactions | 83f55f74-1641-4a6a-bbc0-002f1ade879b |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.